Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-XL
摘要:
Developing potent molecules that inhibit Bcl-2 family mediated apoptosis affords opportunities to treat cancers via reactivation of the cell death machinery. We describe the hit-to-lead development of selective Bcl-X-L inhibitors originating from a high-throughput screening campaign. Small structural changes to the hit compound increased binding affinity more than 300-fold (to IC50 < 20 nM). This molecular series exhibits drug-like characteristics, low molecular weights (M-w < 450) and unprecedented selectivity for Bcl-X-L. Surface plasmon resonance experiments afford strong evidence of binding affinity within the hydrophobic groove of Bcl-X-L. Biological experiments using engineered Mcl-1 deficient mouse embryonic fibroblasts (MEFs, reliant only on Bcl-X-L, for survival) and Bax/Bak deficient MEFs (insensitive to selective activation of Bcl-2-driven apoptosis) support a mechanism-based induction of apoptosis. This manuscript describes the first series of selective small-molecule inhibitors of Bcl-X-L and provides promising leads for the development of efficacious therapeutics against solid tumors and chemoresistant cancer cell lines.
酰基氨基苯并噻唑命中被确定为克氏锥虫复制的潜在抑制剂,锥虫是负责恰加斯病的寄生虫。我们选择化合物1进行铅优化,旨在同时提高其抗克鲁氏锥虫活性(IC 50 = 0.63μM)和其人类代谢稳定性(人类清除率= 9.57 mL / min / g)。总共合成了39种1的类似物,并在体外进行了测试。我们建立了多参数结构与活性的关系,从而可以优化抗寄生虫活性,理化参数和ADME特性。我们将化合物50鉴定为具有改进的体外抗T. cruzi活性的高级铅(IC50 = 0.079μM)和增强的代谢稳定性(人类清除率= 0.41 mL / min / g)和口服途径。在耐受性评估后,有50种药物显示出有希望的体内功效。